We are pleased to inform you that at the end of last year, the USP Group finalized the acquisition of the Hepatil and Magnokal Asparaginian brands, previously owned by Teva, a global leader in the field of generic and innovative drugs.

Hepatil has been present on the Polish market for over 20 years and maintains the position of one of the leading brands in the liver supplement market in Poland. Meanwhile, Magnokal Asparaginian, offered in Poland for over 25 years, is an over-the-counter drug with the combined action of magnesium, potassium, and aspartic acid.

Both the acquisition of Hepatil, one of the largest brands in the liver preparation category, and Magnokal Asparaginian perfectly complement USP Zdrowie’s portfolio, increasing the scale of operations in the OTC market in Poland and is a manifestation of the company’s development strategy in Poland.